Related Experiment Video
Updated: Jun 17, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
[Metformin-associated hepatotoxicity]
S Olivera-González1, B de Escalante-Yangüela, C Velilla-Soriano
1Servicio de Medicina Interna, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España. susana.olivera@yahoo.es
Abstract:
Metformin is an oral biguanide widely used in the management of patients with type 2 diabetes. It produces non-specific gastrointestinal symptoms in 10-30% of the patients. Lactic acidosis is the most serious side effect, so it must not be administered to patients with renal, liver, or heart insufficiency. Only a few cases of hepatotoxicity due to this drug have been documented. We report the case of a patient with type 2 diabetes mellitus and recent use of metformin who developed serious liver injury, followed by a favorable evolution.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Drug toxicity: Drug–Drug Interaction
Drug toxicity: Idiosyncratic Reactions
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
